M&A / Deals Parkinson’s charity partners Biognosys on biomarker project PharmaphorumA new R D project will try to develop assays for LRRK2, a biomarker linked to Parkinson's that has emerged as a major drug target in the disease.M&A / DealsNeuroscienceRead full story pharminent April 15, 2026 Pharmaphorum A new R D project will try to develop assays for LRRK2, a biomarker linked to Parkinson’s that has emerged as a major drug target in the disease. M&A / DealsNeuroscienceRead full story Post navigation Previous: Daiichi exits OTC, with $1.55bn unit sale to SuntoryNext: Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
